ZOMETA Drug Patent Profile

When do Zometa patents expire, and when can generic versions of Zometa launch?

Zometa is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-six patent family members in twenty-two countries.

The generic ingredient in ZOMETA is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zometa

A generic version of ZOMETA was approved as zoledronic acid by DR REDDYS LABS LTD on March 4^th, 2013.

Summary for ZOMETA

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	113
Patent Applications:	4,697
Drug Prices:	Drug price information for ZOMETA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZOMETA
DailyMed Link:	ZOMETA at DailyMed

See drug prices for ZOMETA

Recent Clinical Trials for ZOMETA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Phase 3
Australian and New Zealand Intensive Care Research Centre	Phase 2
Lithuanian University of Health Sciences	N/A

See all ZOMETA clinical trials

Paragraph IV (Patent) Challenges for ZOMETA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOMETA	Injection	zoledronic acid	4 mg/100 mL, 100 mL vial	021223	1	2012-01-31
ZOMETA	Injection	zoledronic acid	0.8 mg (base) /mL	021223	1	2008-06-11

US Patents and Regulatory Information for ZOMETA

ZOMETA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001		DISCN	Yes	No
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003		DISCN	Yes	No
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011		DISCN	Yes	No	7,932,241		Y

Expired US Patents for ZOMETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001	4,777,163
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011	4,939,130*PED
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001	4,939,130*PED
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003	8,324,189*PED
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003	4,939,130*PED
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003	4,777,163
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011	8,324,189*PED

EU/EMA Drug Approvals for ZOMETA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Zoledronic Acid Accord	zoledronic acid	EMEA/H/C/002667Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2014-01-16
Actavis Group PTC ehf	Zoledronic acid Actavis	zoledronic acid	EMEA/H/C/002488Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-04-20
Mylan Pharmaceuticals Limited	Zoledronic acid Mylan	zoledronic acid	EMEA/H/C/002482Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2012-08-23
Pfizer Europe MA EEIG	Zoledronic Acid Hospira	zoledronic acid	EMEA/H/C/0023654 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.	Authorised	yes	no	no	2012-11-19
Teva B.V.	Zoledronic acid Teva	zoledronic acid	EMEA/H/C/002439Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-08-16
Sandoz Pharmaceuticals d.d.	Aclasta	zoledronic acid	EMEA/H/C/000595Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,	Authorised	no	no	no	2005-04-15
Phoenix Labs Unlimited Company	Zometa	zoledronic acid	EMEA/H/C/000336Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	no	no	no	2001-03-20

International Patents for ZOMETA

See the table below for patents covering ZOMETA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	10199052
Greece	3004499
Australia	2004271731	Pharmaceutical products comprising bisphosphonates
Hong Kong	114894	Substituted alkane-diphosphonic acids
World Intellectual Property Organization (WIPO)	0189494
Canada	2536206	PRODUITS PHARMACEUTIQUES CONTENANT DES BISPHOSPHONATES (PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES)
Denmark	609587

Supplementary Protection Certificates for ZOMETA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0275821	2001C/035	Belgium		PRODUCT NAME: ACIDE ZOLEDRONIQUE; NAT. REGISTRATION NO/DATE: EU/1/01/176/001 20010321; FIRST REGISTRATION: CH 55463 20001128
0258618	SPC/GB01/042	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320
0275821	27/2001	Austria		PRODUCT NAME: ZOLEDRONSAEURE UND DEREN SALZE UND HYDRATE; NAT. REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: LI 55463.01 20001128
1591122	132013902140458	Italy		PRODUCT NAME: ACIDO ZOLEDRONICO(ACLASTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/05/308/002, 20071003;57363, 20070927
0258618	26/2001	Austria		PRODUCT NAME: ZOLEDRONSAEURE; NAT. REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: LI 55463 20001128
0275821	01C0035	France		PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128
0275821	SPC/GB01/039	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID OPTIONALLY IN THE FORM OF A SALT THEREOF; NATIONAL REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: CH 55463 20001128

Market Dynamics and Financial Trajectory for ZOMETA (Aredia/Zometa)

Last updated: February 20, 2026

What is ZOMETA, and what is its therapeutic use?

ZOMETA (zoledronic acid) is an intravenous bisphosphonate used primarily to treat skeletal complications in cancer patients with bone metastases, hypercalcemia of malignancy, and certain osteoporosis cases. Approved by the FDA in 2001, ZOMETA targets bone resorption by inhibiting osteoclast activity.

How has ZOMETA's market evolved since approval?

Since its initial approval, ZOMETA has maintained a leading position in oncology supportive care. The drug's revenues peaked around 2010, driven by its widespread adoption in metastatic bone disease. Sales declined gradually starting 2016, influenced by the emergence of alternative therapies and changing treatment guidelines.

Key historical sales data:

Year	Global Sales (USD million)	Notes
2010	1,020	Peak sales, high adoption in cancer-related bone disease
2015	800	Market expansion plateaued
2018	650	Reduction due to increased generic competition
2020	480	Impacted by COVID-19, generic erosion

What factors influence ZOMETA’s current market position?

Market Competition

• Generics: ZOMETA’s patent expiration in 2019 led to increased generic manufacturing, causing price erosion and volume shifts.
• Alternative formulations: Developed by competitors, including oral bisphosphonates like alendronate, reduce intravenous ZOMETA’s market share, especially in osteoporosis treatment.

Therapeutic Guidelines

• Growing clinical emphasis on alternatives such as denosumab (Xgeva, Prolia), which provides similar or superior efficacy for specific indications.

Pricing and Reimbursement

• Price reductions driven by competitive pressures and payer negotiations.
• Reimbursement policies favor newer agents with more convenient dosing.

Regulatory and Patent Landscape

• Patent expiration in 2019 opened the market to generics.
• No significant new indications or formulations have received approvals since then.

How do current sales forecasts look?

Short-term (2023-2027)

• Declining revenue trend expected to continue at an annual rate of 4-6%, driven by generic erosion.
• Estimated global sales around USD 350 million by 2027.

Long-term outlook

• Market share decreases in oncology supportive care.
• Limited growth prospects without new indications or formulation improvements.

Competitor landscape

• Denosumab (Xgeva/Prolia): Dominates the supportive care segment; projected to grow at 8% CAGR through 2027.
• Bisphosphonates (oral): Used mainly in osteoporosis; sales stable but declining for intravenous options.

What are the key risks impacting ZOMETA’s financial trajectory?

• Patent expiry reduces exclusivity, intensifies generic competition.
• Introduction of biosimilars and alternative agents.
• Shifts in clinical guidelines favoring other therapies.
• Pricing pressures from payers seeking cost-effective options.
• Limited pipeline developments or new indications.

What strategic options exist for stakeholders?

• Focus on niche or orphan indications.
• Develop improved formulations (e.g., less infusion-related adverse events).
• Expand into emerging markets with unmet needs.
• Partner with biotechnology firms to develop combination therapies or novel bisphosphonates.
• Invest in marketing efforts emphasizing cost-effectiveness over newer agents.

Summary of Market and Financial Outlook

Aspect	Status/Forecast
Peak sales year	2010
Current market size (2023)	Approx. USD 500 million
Projected sales (2027)	Approx. USD 350 million
Key growth drivers	Emerging markets, niche indications
Key decline factors	Patent expiry, generics, competition from other agents

Key Takeaways

• ZOMETA's revenue peaked over a decade ago; current sales are declining.
• Patent expiration in 2019 led to increased generic competition, contributing to revenue erosion.
• Alternative therapies such as denosumab now dominate the supportive care market.
• Near-term growth prospects remain limited unless new indications or formulations are pursued.
• Market dynamics favor cost-effective, innovative, or niche-focused strategies.

Frequently Asked Questions

1. Is ZOMETA still under patent protection?
No. The patent expired in 2019, allowing generic manufacturers to produce zoledronic acid.

2. What are the main competitors to ZOMETA?
Denosumab (Xgeva, Prolia) is the primary competitor, offering similar or better efficacy for some indications.

3. What impact did the COVID-19 pandemic have on ZOMETA sales?
Sales declined due to reduced hospital visits and treatment delays, further accelerating erosion from generics.

4. Are there any upcoming regulatory approvals for new ZOMETA-related therapies?
No, there are no recent or planned approvals for new formulations or indications.

5. Which markets offer the most growth potential for Zoledronic acid?
Emerging markets and niche indications such as rare bone diseases may offer some growth, although overall market contraction is expected.

---

References

1. Drug Approvals and U.S. Patent Expiry Data. U.S. Food and Drug Administration. (2022).
2. IQVIA. (2022). Pharmaceuticals Market Data.
3. EvaluatePharma. (2022). Global Oncology Market Forecast.
4. U.S. Patent Office. (2019). Patent expiration notices for zoledronic acid.
5. Market Intelligence Reports. (2023). Oncology supportive care drugs competitive landscape.